- Trials with a EudraCT protocol (59)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
59 result(s) found for: Lymphopenia.
Displaying page 1 of 3.
EudraCT Number: 2009-017978-21 | Sponsor Protocol Number: EMR700568-012 | Start Date*: 2010-12-20 | |||||||||||
Sponsor Name:Merck Serono S.A. - Geneva | |||||||||||||
Full Title: Prospective observational long-term safety registry of Multiple Sclerosis patients who have participated in cladribine clinical trials (PREMIERE) | |||||||||||||
Medical condition: Multiple Sclerosis patients who have participated in cladribine tablets clinical trials | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FI (Completed) LT (Completed) AT (Completed) GR (Completed) CZ (Completed) GB (Completed) EE (Completed) LV (Completed) BE (Completed) SE (Completed) PT (Completed) DK (Completed) ES (Completed) IT (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001749-38 | Sponsor Protocol Number: IL2-COVID | Start Date*: 2020-10-02 |
Sponsor Name:Azienda Ospedaliero-Universitaria S. Andrea | ||
Full Title: PET/CT with 68Ga-IL2 for imaging IL2R+ cells in COVID-19+ patients | ||
Medical condition: Evaluation of the inflammatory infiltrate in patients with COVID-19 in order to map the "trafficking" of T-activated lymphocytes and clarify the causes of lymphopenia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005984-29 | Sponsor Protocol Number: NL76248.091.20 | Start Date*: 2021-06-28 |
Sponsor Name:Radboud University Medical Center | ||
Full Title: [89Zr]Df-IAB22M2C anti-CD8 minibody PET/CT imaging to assess the in vivo distribution of CD8+ T-cells in COVID-19 patients | ||
Medical condition: Proven COVID-19. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2007-003086-40 | Sponsor Protocol Number: PIX001 | Start Date*: 2008-04-08 |
Sponsor Name:Fondation Charcot Stichting | ||
Full Title: A Phase I/II Study of Pixantrone in Patients with an Aggressive Relapsing Remitting (RR) or Secondary Progressive (SP) Multiple Sclerosis (PIXAMS) | ||
Medical condition: aggressive relapsing remitting (RR) or secondary progressive (SP) multiple sclerosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Ongoing) BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001437-12 | Sponsor Protocol Number: COVID-19_ASS | Start Date*: 2020-04-09 | |||||||||||
Sponsor Name:Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR) | |||||||||||||
Full Title: Random, controlled, open, one-site clinical trial in adult patients with COVID-19 severe pneumonia treated with immunomodulatory drugs | |||||||||||||
Medical condition: Severe COVID-19 pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001375-32 | Sponsor Protocol Number: PreToVid | Start Date*: 2020-04-03 |
Sponsor Name:UMCG | ||
Full Title: Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial | ||
Medical condition: Hypoxia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-000390-37 | Sponsor Protocol Number: CHD005-17 | Start Date*: 2017-12-01 |
Sponsor Name:Centre Hospitalier Départemental Vendée de la Roche sur Yon | ||
Full Title: Maintaining or Stopping immunosuppressive Therapy in patients with ANCA vasculitis and End-stage Renal disease: a prospective, multicenter, randomized, open-label, clinical trial | ||
Medical condition: End-stage renal disease ANCA vascularitis Immunosuppressive therapy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001022-22 | Sponsor Protocol Number: COV-2-STs | Start Date*: 2021-05-14 |
Sponsor Name:Γενικό Νοσοκομείο Θεσσαλονίκης "Γεώργιος Παπανικολάου" | ||
Full Title: Generation of SARS-CoV-2-specific T lymphocytes from recovered donors and administration to high-risk COVID-19 patients | ||
Medical condition: COVID-19 high-risk patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-019151-22 | Sponsor Protocol Number: FPUVB 004 | Start Date*: 2011-02-24 | |||||||||||
Sponsor Name:Medizinische Universität Wien, Univ.Klinik f.Dermatologie | |||||||||||||
Full Title: Fumaric acid ester versus fumaric acid esters plus narrow band UVB in patients with severe plaque psoriasis | |||||||||||||
Medical condition: Severe Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003774-32 | Sponsor Protocol Number: N/A | Start Date*: 2022-01-26 | |||||||||||
Sponsor Name:DIPARTIMENTO BIOMEDICINA E PREVENZIONE UNIVERSITà DEGLI STUDI DI ROMA TOR VERGATA | |||||||||||||
Full Title: Enhancing Treatment in Persistent Glioblastoma through AGuIX Nanoparticles for Precision Radiotherapy (NanoGBM-Precision): A Phase II, monocenter, open-label, single-arm, no-profit clinical trial. | |||||||||||||
Medical condition: Persistent Glioblastoma Multiforme, grade IV | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006881-19 | Sponsor Protocol Number: TV48574-IMM-20036 | Start Date*: 2022-12-21 | ||||||||||||||||
Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc. | ||||||||||||||||||
Full Title: A 14-Week Phase 2b, RandomizEd, Double-BLind, Dose-Ranging Study to Determine the PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts with Moderate to Severe Ulcerat... | ||||||||||||||||||
Medical condition: Moderate to severe Ulcerative colitis or moderate to severe Crohn's disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Trial now transitioned) ES (Ongoing) SK (Trial now transitioned) PL (Ongoing) AT (Ongoing) DE (Trial now transitioned) IT (Ongoing) CZ (Trial now transitioned) BG (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-007147-28 | Sponsor Protocol Number: CLI-107-07 | Start Date*: 2008-02-29 | |||||||||||
Sponsor Name:CYTHERIS | |||||||||||||
Full Title: A PHASE I/IIa DOSE ESCALATION STUDY OF REPEATED ADMINISTRATION OF “CYT107” (glyco-r-hIL-7) ADD ON TREATMENT IN GENOTYPE 1 or 4 HCV INFECTED PATIENTS RESISTANT TO PEGYLATED INTERFERON-ALPHA AND RIB... | |||||||||||||
Medical condition: Hepatitis C, genotypes 1 and 4 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-010640-34 | Sponsor Protocol Number: THYTOTRA | Start Date*: 2009-08-13 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA | |||||||||||||
Full Title: INDUCTION OF DONOR-SPECIFIC TOLERANCE IN PATIENTS WITH LIVER TRANSPLANTATION WITH RECIPIENT PRE-TREATMENT WITH THYMOGLOBULINE AND MINIMAL POST-TRANSPLANT IMMUNOSUPPRESSION. | |||||||||||||
Medical condition: Adult recipients of first liver transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000670-37 | Sponsor Protocol Number: ESR-17-13332 | Start Date*: 2019-05-09 |
Sponsor Name:Radboud University Medical Center | ||
Full Title: Imaging tumor-infiltrating CD8+ T-cells in non-small cell lung cancer upon neo-adjuvant treatment with Durvalumab (MEDI4736). | ||
Medical condition: Patients with non-small cell lung carcinoma (NSCLC). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003127-41 | Sponsor Protocol Number: BT009E | Start Date*: 2021-05-12 | |||||||||||
Sponsor Name:INSIGHTEC | |||||||||||||
Full Title: Assessment of Safety and Feasibility of Exablate Blood-Brain Barrier Disruption (BBBD) with Microbubble Resonators for the Treatment of Recurrent Glioblastoma (rGBM) in Subjects Undergoing Carbopla... | |||||||||||||
Medical condition: Recurrent Glioblastoma (rGBM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006495-16 | Sponsor Protocol Number: PrEPSo | Start Date*: 2022-02-25 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI" | |||||||||||||
Full Title: Immunogenicity and safety of Sotrovimab (Vir 7831) IV as primary prophylaxis in anti-SARS-CoV-2 vaccine non responders | |||||||||||||
Medical condition: Covid 19 Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002356-37 | Sponsor Protocol Number: VAX-TRES | Start Date*: 2021-09-22 | ||||||||||||||||
Sponsor Name:Fundació Clinic per a la Recerca Biomèdica (FCRB) | ||||||||||||||||||
Full Title: Study about the response to the administration of a third dose of mRNA-1273 vaccine (COVID19 vaccine Moderna) in renal transplants with immunological failure initial to vaccination | ||||||||||||||||||
Medical condition: COVID19 vaccine in kidney transplant patients | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005763-31 | Sponsor Protocol Number: V1.610AUG2020 | Start Date*: 2021-03-15 | |||||||||||
Sponsor Name:Icahn School of Medicine at Mount Sinai | |||||||||||||
Full Title: FREEDOM COVID Anticoagulation Strategy Randomized Trial | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-002782-32 | Sponsor Protocol Number: C13006 | Start Date*: 2009-03-02 | |||||||||||
Sponsor Name:Millennium Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Ulcerative C... | |||||||||||||
Medical condition: Moderate to Severe Ulcerative Colitis Colitis ulcerosa moderada o grave | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) EE (Completed) HU (Completed) AT (Completed) IE (Completed) LV (Completed) CZ (Completed) NL (Completed) DK (Completed) IS (Completed) PT (Prematurely Ended) BE (Completed) FR (Completed) GB (Completed) BG (Completed) IT (Completed) MT (Completed) DE (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002783-33 | Sponsor Protocol Number: C13007 | Start Date*: 2009-03-02 | |||||||||||
Sponsor Name:Millennium Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Crohn?s Dise... | |||||||||||||
Medical condition: Moderate to Severe Crohn's Disease Enfermedad de Crohn moderada o grave | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) EE (Completed) HU (Completed) SK (Completed) AT (Completed) IE (Completed) LV (Completed) CZ (Completed) NL (Completed) IS (Completed) PT (Prematurely Ended) DK (Completed) FR (Completed) BE (Completed) MT (Completed) GB (Completed) BG (Completed) SE (Completed) IT (Completed) DE (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.